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We examined the roles of type 1 and type 2 calsequestrins (CSQ1
and CSQ2) in stored Ca2 release of C2C12 skeletal muscle myo-
tubes. Transduction of C2C12 myoblasts with CSQ1 or CSQ2 small
interfering RNAs effectively reduced the expression of targeted
CSQ protein to near undetectable levels. As compared with control
infected or CSQ1 knockdown myotubes, CSQ2 and CSQ1/CSQ2
knockdownmyotubes had significantly reduced storedCa2 release
evoked by activators of intracellular Ca2 release channel/ryano-
dine receptor (10mM caffeine, 200 M 4-chloro-m-cresol, or 10mM
KCl). Thus, CSQ1 is not essential for effective storedCa2 release in
C2C12 myotubes despite our in vitro studies suggesting that CSQ1
may enhance ryanodine receptor channel activity. Todetermine the
basis of the reduced stored Ca2 release in CSQ2 knockdown myo-
tubes, we performed immunoblot analyses and found a significant
reduction in both sarco/endoplasmic reticulum Ca2-ATPase and
skeletalmuscle ryanodine receptorproteins inCSQ2andCSQ1/CSQ2
knockdown myotubes. Moreover, these knockdown myotubes exhib-
ited reduced Ca2 uptake and reduced stored Ca2 release by UTP
(400 M) that activates a different family of intracellular Ca2 release
channels (inositol 1,4,5-trisphosphate receptors). Taken together, our
data suggest that knocking down CSQ2, but not CSQ1, leads to
reduced Ca2 storage and release in C2C12myotubes.
Calcium release from intracellular stores is a key step in awide variety
of cellular processes (1–3). In striated muscles, the release of stored
Ca2 from the sarcoplasmic reticulum (SR)2 into cytosol by intracellular
Ca2 release channels known as ryanodine receptors (RyRs) initiates
muscle contraction. Subsequently, the sequestration of cytosolic Ca2
back into the SR by the sarcoplasmic/endoplasmic Ca2 ATPase
(SERCA) leads tomuscle relaxation (3). In addition to RyRs and SERCA,
a number of SR proteins also play a significant role in Ca2 storage and
release and therefore may be important in striated muscle function. In
this regard, the high-capacity, low-affinity Ca2-binding protein calse-
questrin (CSQ)hasdrawn increased attention.AlthoughCSQ is thought to
increaseCa2 storage capacityof SR in striatedmuscles (4–6),more recent
studies have suggested that CSQ may also affect stored Ca2 release by
modulating RyR channel activities directly (7–9) or indirectly (10–12).
Murine muscles express two CSQ isoforms that share 60% amino
acid sequence homology (13). Crystal structure analysis has shown that
the two CSQ isoforms form linear polymers as the Ca2 concentration
is increased (14). Type 1CSQ (CSQ1) is expressed in fast-twitch skeletal
muscle and is concentrated in the terminal cisternae of SR (15) where it
interactswith triadin, anRyR-associated protein (8, 16). Consistentwith
its role in Ca2 storage, overexpression of CSQ1 in skeletal muscle-
derived C2C12 myotubes increased Ca2 store size (17). In addition,
CSQ1 has also been shown to modulate skeletal muscle RyR (RyR1)
channel activity directly (7–9) as well as through RyR-associated pro-
teins such as triadin and junction (11, 18). Preliminary studies with a
knock-outmousemodel, null for CSQ1, have suggested that CSQ1 is an
important determinant of skeletal muscle triad (SR-T-tubule) structure
(19). Slow-twitch skeletalmuscle co-expressCSQ1and type2CSQ(CSQ2)
(20–22). In cardiac myocytes, CSQ2 forms a large multiprotein complex
that includes the cardiac RyR (RyR2), triadin, and junctin (23).Overexpres-
sion of CSQ2 in cardiac myocytes increased SR Ca2 levels as well as
impaired SR Ca2 release (24–26). A deficiency in CSQ2 (27) and a CSQ2
missense mutation (D307H) (28) both caused catecholamine-induced
polymorphic ventricular tachycardia in humans. The importance of
CSQ2 in skeletal muscle, however, is not well understood.
To better understand the roles of CSQ1 and CSQ2 in stored Ca2
release of skeletal muscle, we used siRNAs to knockdown CSQ1 and/or
CSQ2 in 8-day-old C2C12 myotubes that otherwise robustly expressed
both CSQ isoforms. After confirming the efficacies as well as specifici-
ties of our gene-silencing approach, RyR channel activities in the pres-
ence or absence of each CSQ isoform were examined using [3H]ryano-
dine binding and single channel recordings. In addition, stored Ca2
release in different experimental groups of C2C12 myotubes evoked by
activators of RyRs was assessed in the absence of extracellular Ca2.
Although our in vitro studies suggest that CSQ1 may enhance RyR
channel activity, CSQ1 knockdown myotubes unexpectedly had pre-
served stored Ca2 release evoked by activators of RyRs. In contrast,
CSQ2 and CSQ1/CSQ2 knockdown myotubes had significantly
reduced stored Ca2 release to the same RyR activators. Our subse-
quent data suggest that CSQ2, but not CSQ1, maintains type 1
SERCA (SERCA1) protein expression and Ca2 sequestration activ-
ity in C2C12 myotubes. Knocking down CSQ2 therefore leads to
reduced Ca2 storage and thus reduced stored Ca2 release in these
cells. In addition, a deficiency in CSQ2 may lead to reduced RyR1
expression in C2C12 myotubes thus further compromising their
stored Ca2 release. A preliminary report of this work has been
presented in abstract form (29).
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EXPERIMENTAL PROCEDURES
Materials—Immature C2C12 skeletal muscle cells (myoblasts) de-
rived from normal adult C3H mouse leg muscles were purchased from
ATCC (Manassas, VA). Double strand recombinant adenoassociated
viral (rAAV) vector was generously provided by Dr. Douglas McCarty
(University of North Carolina, Chapel Hill). Fluo 4-AM was pur-
chased from Molecular Probes (Eugene, OR) and Fura 2-AM was
purchased from TEF LABS (Austin, TX). Goat polyclonal anti-IP3R2
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA), mouse
monoclonal anti-IP3R3 from BD Biosciences, and anti-junctin from
ProSci Incorporated (San Diego, CA). Mouse monoclonal anti-RyR1/
RyR3 IgG (34C clone) was obtained from the Developmental Studies
Hybridoma Bank (University of Iowa). A rabbit polyclonal IgG raised
against a 13-amino acid region specific for RyR3 and a C-terminal cys-
teine (KKRRRGQKVEKPEC) was prepared as described previously (30).
All other primary antibodies were purchased from Affinity Bioreagents
(Golden, CO). [3H]Ryanodine was obtained from PerkinElmer Life Sci-
ences. Phospholipids were from Avanti Polar Lipids (Alabaster, AL). All
other chemicals were obtained from Sigma unless specified otherwise.
Cell Culture—C2C12 myoblasts were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and 1
antibiotics/antimycotics. Myoblasts were seeded at a concentration of
6  105 cells per 10-cm plate and cultured for 48 h to reach 100%
confluence (defined as day 0 myotubes). To induce myogenic differen-
tiation, the growth medium was then changed to differentiation
medium (Dulbecco’s modified Eagle’s medium supplemented with 2%
horse serum and 1 antibiotics/antimycotics) on day 0. The differenti-
ation medium was changed everyday subsequently.
Construction of Vector, Packaging, and Purification of rAAV—The
oligonucleotides encoding the specific siRNA for each CSQ isoform
were inserted into pSilencer-1.0 vector (Ambion, Austin TX) down-
stream of the U6 promoter using ApaI and EcoRI sites. U6 promoter-
driven expression cassettes were inserted into rAAV vector (ptrs-U1a-
RFP-U6) using the KpnI and NotI sites. The ptrs-U1a-RFP-U6 vector
contains red fluorescent protein andwas kindly provided byDr.Douglas
McCarty (University of North Carolina, Chapel Hill). The resulting
vectors are termed rAAV-CSQ1 and rAAV-CSQ2. The sequences of
oligonucleotides encoding the CSQ1 and CSQ2 siRNA were 5-CTGAA-
GAAGACAGCGTTTATTCAAGAGATAAACGCTGTCTTCTTC-
AG-3 and 5-CAGTGGAGATCGTGAATAATTCAAGAGATTATT-
CACGATCTCCACTG-3. BLAST searches confirmed that the selected
oligonucleotide sequences were not homologous to any other genes. A
control sequence of 5-TTCTCCGAACGTGTCACGTTTCAAGAGA-
ACGTGACACGTTCGGAGAA-3 was used to construct rAAV-control
as a negative control. Serum type 2double strand rAAVswere producedby
the triple plasmid cotransfection method and purified by ammonium sul-
fate precipitation and on cesium chloride gradients (31, 32).
Recombinant AAV Transduction—For rAAV transduction, C2C12
myoblasts were seeded at a concentration of 6  105 cells per 10-cm
plate or 1  105 per well in 6-well plates. About 24 h after seeding,
myoblasts were infected with rAAV carrying the CSQ-siRNA silencing
cassette at 1  104 particles/cell and transferred into differentiation
medium 24 h after infection. The differentiation medium was changed
everyday subsequently.
Immunoblot and Immunofluorescence Analyses—Unless otherwise
indicated, 8-day-old C2C12 myotubes grown on 6-well plates were har-
vested, washed twice with cold phosphate-buffered saline, lysed in RIPA
buffer plus protease inhibitors (Complete Mini, Roche Diagnostics), and
centrifuged at 12,000  g for 10 min to remove insoluble material. Protein
concentrationswere determinedusingBCAassay. Twentyg of lysatewas
separated by 10% SDS-PAGE, transferred to polyvinylidene difluoride
membranes, and probedwith antibodies forCSQ1, CSQ2, triadin 95, junc-
tin, 1-DHPR, RyRs, IP3Rs, and SERCA1. Western blots were developed
using 3,3-diaminobenzidine or enhanced chemiluminescence and quanti-
fied usingKodakDigital Science ID ImageAnalysis Software. For immuno-
fluorescence analysis, 8-day-old C2C12 myotubes fixed with 3% paraform-
aldehydewerepermeabilizedwithbuffer containing20mMHEPES, pH7.4,
0.3 M sucrose, 50 mM NaCl, 3 mM MgCl2, and 0.5% Triton X-100, and
incubated with anti-CSQ1 or anti-CSQ2 antibody, followed by incubation
withAlexa Fluor 488-labeled goat anti-mouse or goat anti-rabbit antibody.
Images were analyzed by confocal microscopy.
Preparation of Membrane Fractions—C2C12 myotubes grown on
10-cm tissue culture dishes were washed twice with 3 ml of ice-cold
phosphate-buffered saline containing 5 mM EDTA and harvested in
phosphate-buffered saline containing 5 mM EDTA and protease inhib-
itors by removal from the plates by scraping. Cells were collected by
centrifugation, resuspended in the above solution without EDTA, again
pelleted, and stored at 80 °C. A crude membrane fraction was
obtained by homogenizing the cells in 0.15 M KCl, 20mM imidazole, pH
7, solution containing 0.3 M sucrose, 0.1 mM EDTA, 1 mM glutathione
(oxidized), and protease inhibitors with the use of a Tekmar homoge-
nizer (6 s at 13,500 rpm). Cell homogenates were centrifuged for 30min
at 100,000  g, pellets were resuspended in 0.15 M KCl, 20 mM imidaz-
ole, pH 7, solution containing 0.3 M sucrose and protease inhibitors, and
stored at 135 °C. Proteoliposomes containing purified rabbit skeletal
muscle RyR1 ion channels were prepared in the presence of protease
inhibitors (33).
Purification of Calsequestrins—Rabbit skeletal muscle (6) and canine
cardiac muscle (34) CSQs were purified as described.
Stored Ca2 Release—Stored Ca2 release was determined using the
fluorescent Ca2 indicator dye Fluo 4-AM. 8-Day-old C2C12 myotubes
grown on glass coverslips were washed three times with phosphate-
buffered saline and loaded with 5 M Fluo 4-AM for 1 h at 37 °C in
Krebs-Ringer-Henseleit (KRH) buffer (125mMNaCl, 5mMKCl, 1.2mM
KH2PO4, 6mM glucose, 1.2mMMgCl2, 2mMCaCl2, and 25mMHEPES,
pH 7.4). After loading, cells were rinsed with KRH buffer to remove
non-hydrolyzed fluorophore and kept in KRH buffer for 30min to com-
plete de-esterification. Individual cells in Ca2-free KRH buffer (2 mM
CaCl2 was replaced by 0.5 mM EGTA) were defined as regions of inter-
est, and average fluorescence was measured by using the program
ImageMaster (Photon Technology International, Lawrenceville, NJ).
Resting calcium levels were monitored with Fura-2. Cells were loaded
with 5 M Fura 2-AM and excited alternatively at 340 and 380 nm. The
fluorescence emission was collected at 510 nm. Resting intracellular
calcium concentrations were calculated using the equation: [Ca2]i 
Kd (F380 max/F380 min)(RRmin)/(RmaxR). A dissociation constant (Kd)
of 224 nM (35, 36) was used for the binding of calcium to Fura-2 at 37 °C.
Rmax and Rmin were determined in each experimental group by the con-
secutive addition of 10 M ionomycin and 50 mM EGTA.
Restoring Ca2 Release in CSQ2 Knockdown Myotubes—To deter-
mine whether CSQ2 is specifically responsible for the decreased stored
Ca2 release of C2C12 myotubes treated with CSQ2 siRNA, we per-
formed additional experiments.We first amplified CSQ2 cDNAs from a
mouse skeletal muscle cDNA library (Clontech) by PCR and then con-
structed theCSQ2 cDNAs into PcIneo vector usingNheI andNotI sites.
3 g of PcIneo-CSQ2 plasmid DNA, 1 g of ptrs-U1a-RFP vector (as a
reporter), and 10 nM chemically synthesized siRNA specific for CSQ2
(see above targeting sequence) (Qiagen, Valencia, CA) were thenmixed
in 10 l of Lipofectamine 2000 (Invitrogen) and co-transtected into
C2C12 myoblasts in each well of the 6-well plate. In two other groups of
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C2C12 myoblasts, PcIneo-CSQ2 was replaced by the same amount of
PcIneo vector in one group and CSQ2 siRNA was omitted in the other
group. The transfection efficiency was about 5%. C2C12 myoblasts were
then allowed to differentiate over 8 days and myotubes with red fluo-
rescence were examined for caffeine-induced stored Ca2 release as
described above.
[3H]Ryanodine Binding—Unless otherwise indicated, crude mem-
brane fractions prepared from C2C12 cells were incubated with 2.5
nM [3H]ryanodine in 20 mM imidazole, pH 7.0, 250 mM KCl, 150 mM
sucrose, 1 mM glutathione (oxidized), 20 M leupeptin, and 200 M
Pefabloc, and the indicated free Ca2 concentrations. Nonspecific bind-
ing was determined using a 1000-fold excess of unlabeled ryanodine.
After 20 h at 24 °C, aliquots of the sampleswere dilutedwith 8.5 volumes
of ice-cold water and placed on Whatman GF/B filters preincubated
with 2% polyethyleneimine in water. Filters were washed with 3 5 ml
of ice-cold 0.1MKCl, 1mMK-PIPES, pH7.0. Radioactivity remaining on
the filters was determined by liquid scintillation counting to obtain
bound [3H]ryanodine.
Bmax values of [3H]ryanodine binding were determined by incubating
membranes for 4 h at 24 °C with a saturating concentration of [3H]ry-
anodine (30 nM) in 20 mM imidazole, pH 7.0, 0.6 M KCl, 0.15 M sucrose,
20 M leupeptin, 200 M Pefabloc, and 100 M Ca2. Specific [3H]ry-
anodine binding was determined as described above.
45Ca2 Uptake—ATP-dependent 45Ca2 uptake by C2C12 mem-
branes was determined using a filtration method. 45Ca2 uptake was
initiated by placingmembranes in 0.15 MKCl, 20mM imidazole, pH 7.0,
solution containing 5 mM ATP, 8 mM Mg2, 5 mM Koxalate (a Ca2
precipitating agent to increase Ca2 uptake capacity (37)), 10M ruthe-
nium red (to inhibit RyRs (38)), 5 mM NaN3 (to inhibit mitochondrial
Ca2 uptake), 1 mM EGTA, and 45Ca2 to yield a free Ca2 concentra-
tion of 0.5 M. To obtain 45Ca2 uptake rates, aliquots were placed at
2.5, 5, and 10min on 0.45mMillipore filters under vacuum and rinsed
with three 3-ml volumes of ice-cold 0.175 M KCl, 5 mM imidazole, pH
7.0, solution. Radioactivity remaining with the vesicles on the filters was
determined by liquid scintillation counting.
Single Channel Recordings—Single channel measurements were per-
formed using Mueller-Rudin-type planar lipid bilayers containing a
5:3:2 mixture of bovine brain phosphatidylethanolamine, phosphatidyl-
serine, and phosphatidylcholine (25 mg of total phospholipid/ml of
n-decane) (39). SR vesicles of 8-day-old C2C12 myotubes were added to
the cis (SR cytosolic side) chamber of a bilayer apparatus and fused in the
presence of an osmotic gradient (250mM cisKCl, 20mM transKCl in 20
mM K-HEPES, pH 7.4, with 2 M Ca2). Amounts of membranes were
adjusted to obtain single channel activities not more than 30 min after
their addition. After appearance of channel activity, trans (SR lumenal)
KCl concentration was increased to 250mM to prevent further fusion of
membranes. The trans side of the bilayer was defined as ground. The
large cytosolic regulatory region of the channels faced the cis chamber in
a majority (98%) of the recordings (40). Purified canine cardiac and
rabbit skeletal muscle CSQswere added to the trans chamber. Electrical
signals were filtered at 2 kHz, digitized at 10 kHz, and analyzed as
described (40).
Biochemical Assays and Data Analyses—Free Ca2 concentrations
were obtained by including in the solution the appropriate amounts of
Ca2 and EGTA as determined using the stability constants and pub-
lished computer program (41). Free Ca2 concentrations of 1 M were
verified with the use of a Ca2 selective electrode.
Results are given as mean  S.E. Significance of differences in data
(p 	 0.05) were determined using Student’s t test.
RESULTS
Efficiencies and Specificities of Knocking Down CSQ1 and CSQ2 in
C2C12 Myotubes—C2C12 myoblasts were infected with rAVV vectors
containing the sequences for red fluorescent protein, U6 promoter
(ptrs-U1a-RFP-U6), and CSQ1 or CSQ2 specific siRNA. These C2C12
myoblasts were then allowed to differentiate into multinucleated myo-
tubes over 8 days (Fig. 1) as described under “Experimental Procedures.”
In addition, C2C12 myoblasts were doubly infected to knockdown both
CSQ isoforms or were infected with rAAV vector that contained a con-
trol oligonucleotide sequence. Transduction efficiencies among these
four groups of C2C12 myotubes were all near 100% as judged by the red
fluorescent protein expression of the myotubes. As shown Fig. 1, A–D,
every myotube expressed the red fluorescent protein when examined
using confocal microscopy.
In our preliminary studies, we had found that C2C12 myotubes
robustly expressed both CSQ isoforms after 6 ormore days of culture in
FIGURE 1. Knocking down CSQ1 and CSQ2 in
8-day-old C2C12 myotubes. The high efficacies
of rAAV transduction are indicated by the expres-
sion of double strand RFP in C2C12 myotubes
infected with rAAV-control (A and B) or rAAV-
CSQ1 plus rAAV-CSQ2 (C and D). Insets show the
localization of CSQ1 (E) and CSQ2 (F) in rAAA-con-
trol infected myotubes and the absence of CSQ1
(G) and CSQ2 (H) in rAAV-CSQ1/rAAV-CSQ2-in-
fected C2C12 myotubes.
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differentiation medium (e.g. Fig. 2D). The cellular distribution of CSQ
isoforms in 8-day-old myotubes was then examined after labeling these
cells with anti-CSQ1 or anti-CSQ2 antibody and followed by Alexa
488-conjugated secondary bodies. As shown in Fig. 1, E and F, the two
CSQ isoforms had a similar cellular distribution in 8-day-old (control)
myotubes. Transductions with rAAV-CSQ1 and rAAV-CSQ2 reduced
the corresponding CSQ isoform to nearly undetectable levels in 8-day-
old C2C12myotubes. Representative results are shown in Fig. 1,G andH
(background green fluorescence is barely noticeable).
The efficacies of knocking down the two CSQ isoforms in C2C12
myotubes were confirmed by immunoblot analyses. As with our immu-
nofluorescence studies, CSQ1 and CSQ2 proteins (both had an appar-
ent molecular mass of 60 kDa on gels) in myotubes were reduced to
undetectable levels by their corresponding siRNAs (Fig. 2, A–C). Also
notable were the specificities of CSQ siRNAs. That is, the level of CSQ2
protein was not affected in C2C12 myotubes infected with rAAV-CSQ1
and similarly the level of CSQ1 protein was not affected in C2C12 myo-
tubes infected with rAAV-CSQ2 (Fig. 2, A and B). These results clearly
show that infecting C2C12 myoblasts with rAAV encoding CSQ1- or
CSQ2-specific siRNA sequence results in the specific knockdown of
corresponding CSQ protein in C2C12 myotubes. These results also val-
idated the isoform specificities of anti-CSQ antibodies used in our
immunoblot and immunofluorescence studies. Furthermore, these
results indicate that knocking down one particular CSQ isoform does
not lead to a compensatory overexpression of the other isoform.
The expression levels of CSQ1 and CSQ2 proteins in different stages
of C2C12 myotubes were investigated using a combination of immuno-
blot and protein densitometry analyses. Immunoblot studies revealed
that CSQ1 and CSQ2 were absent in 1-day-old myotubes (Fig. 2D, lane
1). CSQ2 was first detected in 3-day-old myotubes (lane 3) but by day 6
both CSQ isoforms were easily detectable (lane 5). The expression level
of CSQ1 was not altered in 3- or 6-day-old C2C12 cells infected with
rAAV-CSQ2 (Fig. 2D, upper panel, compare lanes 3 and 4, and 5 and 6).
Conversely, transduction with rAAV-CSQ1 had no noticeable effect on
CSQ2 levels in 3- and 6-day-old C2C12 myotubes (Fig. 2D, lower panel).
We were able to estimate the relative expression of CSQ isoforms in
8-day-old myotubes because our knockdown method is highly effica-
cious and knocking down one CSQ isoform does not lead to a compen-
satory overexpression of the other isoform (Fig. 2, A–D). Densitometry
analyses of the Coomassie Blue-stained gels showed that, as compared
with rAAV-control infection, rAAV-CSQ1 infection reduced the CSQ
protein band by 61  4% in 8-day-old myotubes (not shown). In com-
parison, rAAV-CSQ2 transduction reduced the CSQ protein band by
31  5% (n  3). These data suggest that 8-day-old C2C12 myotubes
expressed CSQ1 and CSQ2 at a protein ratio of 2:1 despite the appar-
ent higher signals of CSQ2 bands in immunoblots (Fig. 2D).
Regulation of RyR byCSQ—To investigate how the twoCSQ isoforms
may regulate channel activities of RyR1 and RyR3 (8-day-old C2C12
myotubes expressed both isoforms, Ref. 42, see also below) thereby
affecting stored Ca2 release in skeletal myotubes, we performed single
RyR channel measurements with membranes isolated from 8-day-old
C2C12 myotubes doubly infected with rAAV-CSQ1 and rAAV-CSQ2
and therefore devoid of both CSQ1 and CSQ2 (Fig. 2C). The regulatory
effects of each CSQ isoform as reflected by the changes in RyR channel
open probabilities (Po) were then determined by adding exogenous
purified rabbit skeletal muscle CSQ1 to the trans (SR lumenal) side of
lipid bilayer setup. Because the purified rabbit CSQ1 preparation also
contained CSQ2 as a minor component as determined by immuno-
blot analysis, we also performed a limited number of experiments
with purified canine calsequestrin that contained only CSQ2. Simi-
larly, we studied membranes isolated from rAVV control-infected
myotubes as comparison. To establish well defined cytoplasmic Ca2
concentrations, K rather than Ca2 was used as the current carrier
(43). Fig. 3A shows a representative single channel recording study that
investigated the effects of 4 M purified rabbit skeletal muscle CSQ on
RyR Po. Baseline Po was recorded with 2 M free Ca2 and 1mMATP in
the cis (cytosolic) side of bilayer chamber. Adding 1 mM Ca2 to the
trans (SR lumenal) chamber increased Po recorded from both CSQ1/
CSQ2 depleted and control membranes. The subsequent addition of 4
MCSQ to the trans chamber, however, increased Po fromCSQ-knock-
down but not from control membranes. Table 1 summarizes the aver-
aged Po values of RyRs isolated from control and CSQ1/CSQ2 knock-
down myotubes without and with 1 mM lumenal Ca2 and after the
addition of 2–4 M CSQ. The effect of CSQ was dependent on the
lumenal concentration of Ca2. Adding CSQ in the presence of a low
trans Ca2 concentration (2 M Ca2) had no effect on Po from CSQ
knockdown membranes but Po was significantly enhanced by the sub-
sequent addition of 1 mM Ca2 (Fig. 3B, Table 1).
CSQ was less effective in enhancing channel activities when only
CSQ1 isoform was knocked down. In the presence of 1 mM lumenal
Ca2, addition of 2 M CSQ1 increased CSQ1-depleted RyR channel
activities 1.09  0.03-fold (n  9, p 	 0.05) as compared with 1.75 
0.18-fold increase of Po values of RyRs isolated frommyotubes devoid of
both CSQ1 and CSQ2 isoforms. The modest effect of CSQ1 on CSQ1-
depleted channels suggests that CSQ2 likely remained with these chan-
nels and impeded access of CSQ1.
The regulatory effect of CSQ on RyRs appears to be dependent on
other SR proteins such as triadin and junctin (18). Our single channel
recording studies of purified rabbit skeletal muscle RyR1 indicated that
4M rabbit CSQ had no noticeable enhancing effect on RyR1 Po even in
the presence of 1 mM lumenal Ca2 (data not shown).
FIGURE 2. Immunoblot analyses of C2C12 myotubes. CSQ1 and CSQ2 levels in C2C12
myotubes infected with rAAV-CSQ1 (A), rAAV-CSQ2 (B), or rAAV-CSQ1/rAAV-CSQ2 (C )
were examined using immunoblot techniques. Lane 1, C2C12 myotubes infected with
rAAV-control. Lanes 2– 4, three independent groups of 8-day-old myotubes infected with
rAAV-CSQ. D, time course of CSQ expression in control, rAAV-CSQ1-, or rAAV-CSQ2-in-
fected C2C12 myotubes. Lanes 1, 3, and 5 are control C2C12 myotubes at days 1, 3, and 6.
Lanes 2, 4, and 6 are days 1, 3, and 6 C2C12 myotubes infected by rAAV-CSQ2 (upper row)
and rAAV-CSQ1 (lower row). E, immunoblots were performed on 8-day-old C2C12 myo-
tube lysate. Lane 1, C2C12 myotubes infected with rAAV-control. Lanes 2– 4, C2C12 myo-
tubes infected with rAAV-CSQ1, rAAV-CSQ2, and rAAV-CSQ1/rAAV-CSQ2, respectively.
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In single channel recording studies, CSQ2 purified from canine car-
diac muscle had a more modest enhancing effect on RyR channel activ-
ities as compared with purified rabbit skeletal muscle CSQ. In the pres-
ence of 1 mM lumenal Ca2, adding 2 M CSQ2 caused a small (but
significant) increase in CSQ1/CSQ2-depleted RyR single channel activ-
ities (Po  0.24  0.05 versus 0.29  0.06, n  7, p 	 0.05).
The effects of rabbit CSQ on RyR channel activities were examined fur-
ther. Fig. 4 shows that a fairly wide range of CSQ concentrations (0.4–4
M) was effective in increasing channel open probability by 1.5–2-fold. A
higher CSQ concentration of 12 M returned Po to near control levels.
Control measurements showed that this decrease was not because of a
change in lumenal Ca2 concentration. Kinetic analysis showed that CSQ
(in the presence of 1mM lumenalCa2) increasedPo by raising the number
of single channel events without significantly changing the mean open
times (Table 2). Taken together, the results of our single channel measure-
ments suggest that rabbit CSQ (which contains CSQ1 as the major com-
ponent), and to a smaller extent canine CSQ2, enhance C2C12 myotube
RyR channel activities in the presence of 1mM luminal Ca2 by increasing
the transition rates from the closed to open states.
We also tested the possibility that CSQ knockdown affected the Ca2
dependence of RyR activities isolated from CSQ knockdown and con-
trol myotubes, using the RyR-specific probe ryanodine (3, 44). Fig. 5
shows that knockdown of CSQ1, CSQ2, and both isoforms did not
significantly alter the bimodal Ca2 dependence of RyR activity.
FIGURE 3. Effects of rabbit skeletal CSQ on sin-
gle RyR channel activity. A, membranes isolated
from C2C12 myotubes infected with rAAV-control
(left) and rAAV-CSQ1/rAAV-CSQ2 (right) were
fused with lipid bilayer. Single channel currents
(downward deflections from closed levels, c–)
were recorded at 20 mV as described under
“Experimental Procedures” in the absence (top
traces) and presence of 1 mM Ca2 trans (middle
traces) and 1 mM Ca2 trans plus purified rabbit
skeletal muscle 4 M CSQ trans (bottom traces). B,
single channel currents were recorded as in A in
the absence (top traces) and presence of 4 M CSQ
trans (middle traces) and 4 M CSQ trans plus 1 mM
Ca2 trans (bottom traces).
TABLE 1
Effects of SR lumenal Ca2 and purified rabbit skeletal muscle CSQ
on RyR single channel activities from control and CSQ1/CSQ2
knockdown myotubes
SR lumenal rabbit skeletal muscle CSQ concentration was 2–4 M. Data are the
mean  S.E. of number of experiments indicated in parentheses. Included in these




2 M Ca2 cis  1 mM ATP cis 0.12  0.03(9) 0.17  0.02(9)
1 mM Ca2 trans 0.25  0.06a 0.24  0.04a
1 mM Ca2 trans  CSQ trans 0.25  0.07a 0.40  0.07a,b
2 M Ca2 cis  1 mM ATP cis 0.16  0.05(5) 0.21  0.03(4)
CSQ trans 0.14  0.02 0.20  0.04
CSQ trans  1 mM Ca2 trans 0.26  0.04a,c 0.33  0.03a,c
a p 	 0.05 versus 2 M Ca2 cis  1 mM ATP cis.
b p 	 0.05 versus 1 mM trans Ca2.
c p 	 0.05 versus 2–4 M CSQ trans.
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Stored Ca2 Release in CSQ KnockdownMyotubes Provoked by Acti-
vators of Intracellular Ca2 Release Channels—Because our single
channel recording studies suggest that both CSQ1 and CSQ2 may
enhance stored Ca2 release by RyRs in C2C12 myotubes, we then tried
to correlate these results with the effects of CSQ knockdown on stored
Ca2 release in intact myotubes using the fluorescent Ca2 indicator
Fluo-4 in the absence of extracellular Ca2. In initial experiments using
the fluorescent Ca2 indicator Fura-2, we determined that there was no
significant difference in the resting cytosolic Ca2 concentration of
control and each of the three CSQ-knockdown myotube groups (data
not shown). Depolarization-induced, RyR-mediated stored Ca2
release in 8-day-oldmyotubeswas provoked by 10mMKCl. StoredCa2
release, as reflected by the Fluo-4 fluorescence over baseline fluores-
cence ratio (F/Fo), was significantly smaller in CSQ2 and CSQ1/CSQ2
knockdownmyotubes (Fig. 6A) as comparedwith the controlmyotubes.
The peak F/Fo ratio was 3.2 0.1 for the control group, 2.4 0.2 for the
CSQ2knockdowngroup, and 2.2 0.2 for theCSQ1/CSQ2knockdown
group (Table 3). In contrast, the peak F/Fo in CSQ1 knockdown myo-
tubes induced by 10 mM KCl was comparable with the control myo-
tubes. To confirm that RyR-mediated stored Ca2 release is reduced in
CSQ2 knockdown myotubes, we also treated the four groups of C2C12
myotubes with caffeine (which activates RyR1 and RyR3 independent of
the DHPR) or 4-chloro-m-cresol (which activates RyR1 but not RyR3
(45)) (the 8-day-old C2C12 myotubes expressed both RyR1 and RyR3
(Fig. 2E)). Indeed, the Ca2 responses of 8-day-old C2C12 myotubes to
10 mM caffeine or 200 M 4-chloro-m-cresol in the absence of extracel-
lular Ca2 were also significantly decreased in CSQ2 and CSQ1/CSQ2
but not in CSQ1 knockdown myotubes (Fig. 6, B and C, Table 3).
Todeterminewhether the lackofCSQ2 is specifically responsible for the
reduced storedCa2 release ofC2C12myotubes treatedwithCSQ2 siRNA,
FIGURE 4. Channel activities of RyR as a function
of CSQ concentration. Single channel activities
were determined as described in the legend to
Fig. 3 in the presence of the indicated concentra-
tions of purified rabbit skeletal muscle CSQ and 1
mM trans (SR lumenal) Ca2. Data are the mean 
S.E. of four to nine experiments. *, p 	 0.05 com-
pared with control (without CSQ).
FIGURE 5. Ca2 dependence of [3H]ryanodine binding to control and CSQ-knock-
down C2C12 myotubes. Specific [
3H]ryanodine binding was determined in 250 mM KCl,
20 mM imidazole, pH 7.0, media containing 2.5 nM [3H]ryanodine and the indicated con-
centrations of free Ca2. Data are mean  S.E. of three to four experiments.
TABLE 2
Effects of SR lumenal Ca2 and CSQ on kinetic parameters of single channel recordings
SR lumenal rabbit skeletalmuscle calsequestrin (CSQ) concentrationwas 2–4M.Average normalized parameters (in the absence of 1mMCa2 CSQ) at 2MCa2 cis 1mM
ATP ciswere for control and CSQ1/CSQ2-depleted RyRs, respectively: Po  0.13  0.05 and 0.15  0.04, Events/min  7,763  858 and 10,114  2,284, To  1.00  0.33
and 0.94  0.14 ms, Tc  7.44  1.17 and 6.67  1.26 ms. Channel parameters were calculated from 6 recordings each that contained a single channel activity.
Additions Po Events To Tc
min1 ms
Control
2 M Ca2 cis  1 mM ATP cis 100 100 100 100
1 mM Ca2 trans 243  38a 221  34a 92  9 34  7a
1 mM Ca2 trans  CSQ trans 256  34a 262  40a 90  7 35  9a
CSQ1/CSQ2 knockdown
2 M Ca2 cis  1 mM ATP cis 100 100 100 100
1 mM Ca2 trans 154  19 a 220  41a 82  17 42  6a
1 mM Ca2 trans  CSQ trans 277  33a,b 296  49 a 116  33 25  6a,b
a p 	 0.05 compared with 2 M Ca2 cis  1 mM ATP cis.
b p 	 0.05 compared with 1 mM Ca2 trans addition.
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C2C12myoblasts were treatedwith the sameCSQ2 siRNAbut synthesized
chemically with or without co-transfection with a plasmid containing the
sequence of CSQ2. Another group of myotubes was used as control (see
“Experimental Procedures”). In these experiments, the peak fluorescences
(F/Fo) were 3.0 0.1 (n 7) for controlmyotubes and 2.1 0.1 (n 8) for
myotubes treatedwithCSQ2 siRNA (p	 0.05).We found that themarked
reduction in caffeine-induced stored Ca2 release caused by CSQ2 siRNA
is partially restored in myotubes co-transfected with CSQ2 siRNA and a
plasmidcontaining the sequenceofCSQ2 (F/Fo2.70.1,n6,p	0.05
as compared with CSQ2 siRNAmyotubes). These results suggest that the
reduction in stored Ca2 release in CSQ2 siRNA-treated myotubes was
specific with regard to CSQ2 knockdown.
FIGURE 6. Effects of CSQ knockdown on stored Ca2 release in C2C12 myotubes. Depolarization (10 mM KCl addition) (A), caffeine (10 mM) (B), and 4-chloro-m-cresol (200 M) (C)
induced Ca2 release were determined in Ca2-free KRH bath solutions as changes of Fluo 4 fluorescence (F/Fo) in C2C12 myotubes infected with rAAV-control (top traces), rAAV-CSQ1
(second traces), rAAV-CSQ2 (third traces), and rAAV-CSQ1/rAAV-CSQ2 (bottom traces).
TABLE 3
Effects of CSQ knockdown on stored Ca2 release in C2C12 myotubes




CSQ1 knockdown CSQ2 knockdown CSQ1/CSQ2knockdown
10 mM KCl 3.2  0.1 3.1  0.2 2.4  0.2a 2.2  0.2a
10 mM Caffeine 3.1  0.1 2.9  0.2 2.5  0.3a 2.1  0.2a
200 M 4-Chloro-m-cresol 2.9  0.1 2.9  0.2 2.3  0.1a 2.2  0.2a
1 M Thapsigargin 3.0  0.1 3.0  0.2 2.3  0.1a 2.0  0.1a
400 M UTP 2.9  0.2 2.9  0.3 2.2  0.2a 2.3  0.1a
a p 	 0.05 compared to control.
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The above results suggest that CSQ2 knockdown may impair Ca2
storage in C2C12 myotubes thereby leading to reduced Ca2 release.
This possibility was further explored using pharmacological agents that
empty Ca2 stores in these myotubes but not through RyRs. In initial
studies, we found that, in the absence of extracellular Ca2, neither
adding UTP (an activator of IP3Rs, 400 M) following caffeine nor add-
ing caffeine following UTP elicited an additional increase in Fluo-4 flu-
orescence in control and CSQ1/CSQ2 knockdown myotubes (not
shown), thus suggesting that the two intracellular Ca2 channel families
release stored Ca2 from the same stores. The effects of CSQ knock-
down on IP3R-mediated Ca2 release were then determined by adding
400 M UTP to the four groups of C2C12 myotubes in Ca2-free KRH
bath solutions. UTP elicited significantly less Ca2 release in rAVV-
CSQ2 and rAVV-CSQ1/rAVV-CSQ2-infected C2C12 myotubes as
compared with rAVV-control and rAVV-CSQ1-infected myotubes
(Table 3). Consistently, in the absence of extracellular Ca2, thapsigar-
gin (which empties intracellular Ca2 stores by inhibiting SERCA1) also
elicited significantly less Ca2 responses in rAVV-CSQ2 and in rAVV-
CSQ1/rAVV-CSQ2-infected C2C12 myotubes (Table 3). We conclude
that knocking down CSQ2 reduces SR Ca2 stores and Ca2 release in
8-day-old C2C12 myotubes.
Immunoblot Analyses of C2C12 Myotube Ca2 Channels and Trans-
porters—Because our Ca2 transient measurements unexpectedly
showed that CSQ2, but not CSQ1, is important for effective storedCa2
release in C2C12 myotubes, we then undertook comprehensive immu-
noblot analyses to determine how knocking down each of the two CSQ
isoforms may alter the expression of Ca2 channels and transporters
that may affect stored Ca2 release in C2C12 myotubes. The immuno-
blot analyses showed that the combined RyR (RyR1 and RyR3) protein
levels in CSQ2 and CSQ1/CSQ2 knockdownmyotubes were decreased
by 27 5 and 30 6% (n 3, p	 0.05), respectively, as compared with
control and CSQ1 knockdown myotubes (Fig. 2E) (n  3). SERCA1
protein levels were reduced by 50  8 and 57  7% (n  3, p 	 0.05) in
CSQ2 and CSQ1/CSQ2 knockdownmyotubes, respectively (Fig. 2E), as
compared with the other two groups. In contrast, no differences in
RyR3, IP3R 1–3, triadin, junctin, or the 1 subunit of L-type Ca2 chan-
nel (1-DHPR) protein expression were detected among the four
groups of C2C12 myotubes, as compared with the actin control.
The decreased protein expression of RyRs was also supported by a
ligand binding assay, using the RyR-specific probe ryanodine. Bmax val-
ues of [3H]ryanodine binding were similar in CSQ1 knockdown and
control myotubes (Table 4). CSQ2 and CSQ1/CSQ2 knockdown myo-
tubes had reduced Bmax values of [3H]ryanodine binding (0.21 and 0.24
pmol/mg of protein, respectively, versus control value of 0.35 pmol/mg
of protein), which suggests a lower RyR protein expression as compared
with control myotubes (Table 4). Most of this decrease could be
accounted for by RyR1 (Fig. 2E).
Knocking Down CSQ2 but Not CSQ1 Reduces Ca2 Uptake by the
SR—To determine whether the decrease in SERCA1 protein expression
among CSQ2 knockdown myotubes may also explain their reduced
stored Ca2 release, SERCA1 activities in the four different groups of
myotubes were determined by measuring the 45Ca2 uptake rates of
isolated membrane preparations. In agreement with the reduced
SERCA1 protein levels (Fig. 2E), 45Ca2 uptake rates of membranes
isolated from CSQ2 and CSQ1/CSQ2 knockdown myotubes were sig-
nificantly lower than those of controls and CSQ1 knockdownmyotubes
(7.8 and 8.4 versus 18.6 and 16.5 nmol/mg protein/min, respectively)
(Table 4). Thus, CSQ2 knockdown may impair Ca2 storage in C2C12
myotubes. In combination with the data presented in Table 3, we con-
clude that knocking down CSQ2 reduces cytosolic Ca2 sequestration
and thereby may reduce Ca2 stores and Ca2 release in 8-day-old
C2C12 myotubes.
DISCUSSION
In fast-twitch skeletal muscle CSQ2 is highly expressed during the
fetal stage but then is gradually replaced by CSQ1 (20, 46). In slow-
twitch skeletal muscle the two CSQ isoforms are co-expressed in adult
animals (22, 47). X-ray crystallographic analyses have indicated that the
two CSQ isoforms have almost identical crystal structures and form
polymers as the Ca2 concentration in the SR increases. Whether the
two CSQ isoforms perform redundant or specific functions in skeletal
muscle remains poorly understood. Herein we described an efficacious
and specific knockdown method that allowed us to differentiate the
roles of the two CSQ isoforms in stored Ca2 release of skeletal muscle
cell line C2C12 myotubes. CSQ proteins in skeletal muscle have a half-
life of 5 days (49) and thus are difficult to knockdown once expressed.
Accordingly, we infected C2C12 myoblasts with rAVV vectors contain-
ing CSQ siRNA sequences before these cells mature into CSQ-express-
ing myotubes. Both CSQ proteins were absent or barely detectable in
1-day-old (control) myotubes but became easily detectable 3 (CSQ2) to
6 (CSQ1) days after forming myotubes. A similar time course of CSQ
mRNA expression inmaturing C2C12 myotubes had been reported pre-
viously (46). Therefore, the high efficacies of CSQ knockdowns in our
study are probably in part due to the timing of CSQ siRNAs delivery.
Moreover, we found that knocking down one CSQ isoform did not
decrease the expression nor caused a compensatory overexpression of
the other isoform in C2C12 myotubes. The high efficacies and specific-
ities of our knockdown approach thus enable us to attribute the
observed functional changes of C2C12 myotubes to a specific CSQ
knockdown rather than to the nonspecific effects of rAAV infection.
C2C12 myotubes with knockdown of both CSQ isoforms provided
membranes that contained RyR1 and RyR3 and associated proteins
(triadin and junction) but depleted of CSQ proteins. Accordingly, we
measured the single channel activities of skeletal RyRs in these mem-
branes before and after adding individual CSQ isoform exogenously as
previous reports have suggested that in striated muscles CSQ forms a
tight multiprotein complex with RyRs and modulates the Ca2 release
of RyRs indirectly via a linkage protein, triadin.We found that bothCSQ
isolated from rabbit skeletal muscle (which is largely CSQ1) and CSQ
isolated from canine heart (CSQ2) individually enhanced RyR channel
opening probabilities in the presence of high lumenal Ca2 concentra-
tions (1 mM), although the effect of CSQ2 was much smaller but never-
theless statistically significant (adding 2 M CSQ2 increased Po from
0.24  0.05 to 0.29  0.06, p 	 0.05). In contrast, adding rabbit skeletal
muscle CSQ had no effect on the channel activities of RyRs in mem-
branes isolated from control C2C12 myotubes under identical condi-
tions. These data indeed support the notion thatCSQproteins forma tight
TABLE 4
Bmax values of 

3Hryanodine binding and 45Ca2 uptake rates
of membranes isolated from control and CSQ knockdown
C2C12 myotubes
The total number of 
3Hryanodine binding sites (Bmax) and 45Ca2 uptake rates of
crudemembrane fractions were determined as described under “Experimental Pro-
cedures.” Data are the mean  S.E. of three to eight experiments.





pmol/mg protein nmol/mg protein/min
Control 0.35  0.04 18.6  3.5
CSQ1 knockdown 0.35  0.04 16.5  3.4
CSQ2 knockdown 0.21  0.03a 7.8  2.3a
CSQ1/CSQ2 knockdown 0.24  0.02a 8.4  2.1a
a p 	 0.05 compared to control.
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protein complexwith skeletal RyRs that rendered these channels fromcon-
trol C2C12 myotubes insensitive to exogenously added CSQ. Moreover,
because exogenously added CSQ proteins had no channel modulating
effectonpurifiedskeletalmuscleRyRs,ourdataalso support thenotion that
CSQ proteins (especially CSQ1) may indirectly facilitate stored Ca2
release by skeletal RyRs via linkage protein(s) (50, 51).
It is therefore unexpected that we consistently found that knocking
down CSQ2, but not CSQ1, reduced stored Ca2 release in C2C12 myo-
tubes especially that in 8-day-old C2C12 myotubes CSQ2 accounts for
only one-third of CSQ proteins by densitometry analysis. We observed
the reduction of stored Ca2 release in CSQ2 knockdown (and double
CSQ knockdown) myotubes caused by all three RyR activators that act
on different skeletal RyR sites. It is therefore unlikely that knocking
down CSQ2 reduces skeletal RyR Ca2 release via specific allosteric
mechanisms, such as disrupting the functional linkage between the
DHPR andRyR1 required for activation of RyR1 by depolarization (KCl)
(52). Moreover, we observed a similar reduction in stored Ca2 release
in CSQ2 knockdown myotubes induced by an activator of IP3Rs (400
MUTP) (48) and by thapsigargin (1M), an inhibitor of SERCA (Table
3). Taken together, these data suggest that knocking down CSQ2 leads
to a reduction in Ca2 storage in C2C12 myotubes thereby leading to a
general reduction in stored Ca2 release.
In agreementwith Beard et al. (18), lumenal CSQdid not affect single,
purified single RyR1 channel activities or channels from control myo-
tubes, presumably because CSQ remained with control channels. How-
ever, we found that RyR channels from CSQ1/CSQ2 knockdown C2C12
myotubes were activated by purified skeletal and cardiac muscle CSQ,
whereas CSQ inhibited the CSQ-depleted RyR1 channel complex (11).
The reason for this discrepancy is not clear but could arise from differ-
ent preparations and experimental conditions used by Beard et al. (11)
and us. One difference was that skeletal SR vesicles predominantly con-
tain RyR1 (18), whereas C2C12 myotubes express RyR1 and RyR3. How-
ever, we observed an inactivation of CSQ-depleted channel activities by
the purified CSQs in only 1 (of 18) single channel recording, which
suggests that both RyR1 and RyR3 were likely activated by CSQ. There
are also certain limitations in using high salt concentrations or knocking
down CSQs. The use of high salt and Ca2 concentrations might have
resulted in an irreversible rearrangement of the RyR1 protein complex,
an incomplete removal of CSQ, or loss of other proteins. CSQ knock-
downmay affect another yet to be identified protein involved in RyR and
CSQ complex interaction, which could have resulted in the lower chan-
nel activities (Po values) recorded with control membranes compared
withmembranes devoid of CSQ1/CSQ2.Whether CSQmodulates RyR
activity directly or via triadin and junctin or an unidentified associated
protein remains an open question.
Our immunoblot analyses suggest that the reduction in Ca2 store
size in CSQ2 knockdownmyotubes is at least in part due to a reduction
of expression of SERCA1 protein. The expression of SERCA1 protein in
CSQ2 and CSQ1/CSQ2 knockdown myotubes is 50% of the control
and the CSQ1 knockdown myotubes. This reduction in SERCA1 had a
large functional significance, as the Ca2 uptake rate by SR vesicles
prepared from CSQ2 or CSQ1/CSQ2 knockdown myotubes was also
decreased by 50%. At this point, the reduction of SERCA1 protein
expression in CSQ2 knockdownmyotubes remains unexplained. As the
expression of other SR proteins, such as junctin, triadin, and RyR3, is
mostly preserved in CSQ2 knockdown myotubes, it is unlikely that
knocking down CSQ2 caused a general retardation of C2C12 myotube
maturation. However, it is notable that RyR1 expression appears to be
decreased in CSQ2 knockdown myotubes. The reduction of RyR1 pro-
tein in CSQ2 knockdown myotubes is supported by a significant
decrease in [3H]ryanodine binding of membranes isolated from CSQ2
knockdown myotubes. The etiology and the functional significance of
this reduction in RyR1 protein expression are currently unknown. To
determine whether knocking down CSQ2 reduces SERCA1 and RyR1
protein expression in C2C12 myotubes at the mRNA level, we are cur-
rently undertaking comprehensive quantitative real-time reverse tran-
scriptase-PCR analyses of the four experimental C2C12myotube groups.
Effectively knocking down CSQ1 and CSQ2 in our study leads to a
few unexpected findings that challenge the traditional views of the roles
of these proteins in skeletal muscle. In particular, knocking down CSQ1
had no noticeable effects on Ca2 storage and stored Ca2 release in
C2C12 myotubes despite extensive prior data suggesting the roles of
CSQ1 in buffering Ca2 in the SR and inmodulating RyR channel activ-
ities (4–9). In this study we have ruled out that CSQ1 knockdown leads
to a compensatory overexpression of the other CSQ isoform thereby
masking the functional roles of CSQ1 in stored Ca2 release in C2C12
myotubes. The next step in defining the functional roles of CSQ1 and
CSQ2would be the deletion of the twoCSQ2 genes in skeletalmuscle of
mice and then study these animals for functional alterations in skeletal
muscle. As a deficiency in CSQ2 protein may lead to fatal cardiac
arrhythmia in young children (27), selective knock-out of CSQ2 in the
skeletal muscle of mice may be necessary.
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